Evidence mapPaperPMID 40298967Full record

ReviewDer Nervenarzt2025

[Attention deficit/hyperactivity disorder and cardiometabolic diseases: prevalence, etiology and treatment].

Sarah Kittel-Schneider

Abstract readReviewEnglish Abstract
In one paragraph

Review in Der Nervenarzt, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Sarah Kittel-SchneiderDepartment of Psychiatry and Neurobehavioural Science, Acute Adult Mental Health Unit, Cork University Hospital, University College Cork, T12DC4A, Wilton, Cork, Irland. skittelschneider@ucc.ie.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a close connection throughout the lifespan between attention deficit/hyperactivity disorder (ADHD) and an increased risk of cardiometabolic diseases, such as obesity, diabetes mellitus and arterial hypertension. According to current knowledge, the causes are genetic factors, dopamine metabolism disorders, circadian rhythm disorders, inflammatory processes and, last but not least, an unhealthy lifestyle. The treatment of individuals with ADHD and comorbid cardiometabolic diseases requires an individualized approach with lifestyle changes, psychotherapy and pharmacotherapy, taking possible cardiometabolic side effects of the ADHD medication into account.

Indexed as

Attention Deficit Disorder with HyperactivityCardiovascular DiseasesChildCombined Modality TherapyComorbidityEvidence-Based MedicineHumansObesityPrevalencePsychotherapyCardiovascular diseasesGeneticsLifestyleMetabolic diseasesObesity

Identifiers

PMID40298967
PMCPMC12058937

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.